title: [TET2 and DLK1 gene expression and their clinical significance in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome].
abstract: OBJECTIVE
  To investigate the expression of TET2 and DLK1 mRNA in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome (MDS) and their clinical significance and to explore the potential mechanism of abnormal cell-mediated immunity.
  
  
  METHODS
  CD(3)(+) T cells were sorted by magnetic activated cell-sorting system. The expressions of TET2 and DLK1 mRNA in bone marrow CD(3)(+) T cells from 26 MDS patients and 16 healthy controls were detected by fluorescence quantitative PCR.
  
  
  RESULTS
  The expression of TET2 mRNA in CD(3)(+) T cells was down-regulated in the MDS patients by (0.16 ± 0.15) fold compared with the controls (P < 0.05). The expression of TET2 mRNA in CD(3)(+) T cells of MDS patients was positively correlated with serum complement C(3) (r = 0.404, P < 0.05). The expression of DLK1 mRNA in CD(3)(+) T cells was up-regulated in the MDS patients by (1.61 ± 0.88) folds compared with the controls (P < 0.05). Grouped by the chromosomes, the patients with chromosome abnormalities presented significantly higher DLK1 mRNA level than those with normal chromosomes [(1.45 ± 0.44) folds, P < 0.05]. The expression of DLK1 mRNA in CD(3)(+) T cells of MDS patients was positively correlated with the proportion of bone marrow blasts (r = 0.343, P < 0.05).
  
  
  CONCLUSIONS
  The mRNA expression of TET2 in CD(3)(+) T cells of MDS patients was decreased while the mRNA expression of DLK1 was increased, which might decline the immune surveillance function. The findings would be useful for exploring the mechanism of immune tolerance.
authors.affiliation: Department of Hematology and Oncology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Rong
authors.initials: R
authors.lastname: Fu
authors.forename: Hua-quan
authors.initials: HQ
authors.lastname: Wang
authors.forename: Li-juan
authors.initials: LJ
authors.lastname: Li
authors.forename: Lan-zhu
authors.initials: LZ
authors.lastname: Yue
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Wen
authors.initials: W
authors.lastname: Qu
authors.forename: Yong
authors.initials: Y
authors.lastname: Liang
authors.forename: Guo-jin
authors.initials: GJ
authors.lastname: Wang
authors.forename: Xiao-ming
authors.initials: XM
authors.lastname: Wang
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Wu
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Jia
authors.initials: J
authors.lastname: Song
authors.forename: Jing
authors.initials: J
authors.lastname: Guan
authors.forename: Li-min
authors.initials: LM
authors.lastname: Xing
authors.forename: Zong-hong
authors.initials: ZH
authors.lastname: Shao
mesh_terms: D000328:Adult; D000368:Aged; D001854:Bone Marrow Cells / Q000276:immunology / Q000378:metabolism; D002135:Calcium-Binding Proteins; D016022:Case-Control Studies; D002869:Chromosome Aberrations; D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D005260:Female; D015870:Gene Expression; D006801:Humans; D007111:Immunity, Cellular / Q000235:genetics / Q000276:immunology; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics*; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
chemical_list: D002135:Calcium-Binding Proteins; C512941:DLK1 protein, human; D004268:DNA-Binding Proteins; D036341:Intercellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D049308:Dioxygenases; C541081:TET2 protein, human